Bernzott Capital Advisors Halozyme Therapeutics, Inc. Transaction History

Bernzott Capital Advisors

$204 Million
Q2 2024

A detailed history of Bernzott Capital Advisors transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Bernzott Capital Advisors holds 187,249 shares of HALO stock, worth $11.1 Million. This represents 4.82% of its overall portfolio holdings.

Number of Shares

187,249

Previous 209,804 10.75%

Holding current value

$11.1 Million

Previous $8.53 Million 14.88%

% of portfolio

4.82%

Previous 3.59%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	SELL	$37.81 - $52.4 $852,804 - $1.18 Million	-22,555 Reduced 10.75%	187,249 $9.8 Million
Q1 2024 May 01, 2024	BUY	$33.68 - $41.95 $2.86 Million - $3.56 Million	84,825 Added 67.87%	209,804 $8.53 Million
Q4 2023 Feb 12, 2024	SELL	$33.32 - $42.1 $1.56 Million - $1.97 Million	-46,829 Reduced 27.26%	124,979 $4.62 Million
Q3 2023 Oct 23, 2023	SELL	$36.46 - $44.03 $4.82 Million - $5.82 Million	-132,201 Reduced 43.49%	171,808 $6.56 Million
Q2 2023 Jul 27, 2023	SELL	$30.28 - $38.74 $527,053 - $674,308	-17,406 Reduced 5.42%	304,009 $11 Million
Q1 2023 Apr 27, 2023	SELL	$32.86 - $55.7 $4.05 Million - $6.87 Million	-123,313 Reduced 27.73%	321,415 $12.3 Million
Q4 2022 Jan 18, 2023	SELL	$40.06 - $59.44 $434,851 - $645,221	-10,855 Reduced 2.38%	444,728 $0
Q3 2022 Dec 22, 2022	SELL	$38.53 - $51.78 $3.24 Million - $4.35 Million	-84,085 Reduced 15.58%	455,583 $18 Million
Q3 2022 Oct 18, 2022	BUY	$38.53 - $51.78 $6.43 Million - $8.64 Million	166,850 Added 44.75%	539,668 $21.3 Million
Q2 2022 Jul 25, 2022	BUY	$37.35 - $48.3 $4.36 Million - $5.63 Million	116,633 Added 45.53%	372,818 $16.4 Million
Q1 2022 Apr 20, 2022	BUY	$31.97 - $41.06 $8.19 Million - $10.5 Million	256,185 New	256,185 $10.2 Million

Others Institutions Holding HALO

# of Institutions

487

Shares Held

123M

Call Options Held

208K

Put Options Held

66.3K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.24B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bernzott Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Bernzott Capital Advisors with notifications on news.

Account

Bernzott Capital Advisors Halozyme Therapeutics, Inc. Transaction History